Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GV-971 Capsules in Healthy Chinese Males
NCT02986529Phase 1Completed
- Sponsor
- Green Valley
- Start
- Nov 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sodium oligomannate in Alzheimer's disease (AD) (3 arms), sponsored by Green Valley. Primary endpoints: Maximum Observed Concentration at 3 days, Area Under the Concentration-Time Curve from Zero to Last Measurable Concentration at 3 days and 1 more. Started Nov 2016; status: completed.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02986529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02986529.